Portal de Murcia
www.portaldemurcia.com
María Dolores Miranda Rollón has analyzed the genetic influence on the response to treatment with Ranibizumab to treat vision loss caused by age-related macular degeneration.
The UCAM intensifies the research activity in Cartagena.
In this context, María Dolores Miranda Rollón has managed to obtain a doctorate after defending the first doctoral thesis by UCAM at the University Hospital of Santa Lucía in Cartagena, which contributes to increase the scientific activity of the port city.
Miranda Rollón has analyzed the genetic influence on the response to treatment with Ranibizumab to treat vision loss caused by age-related macular degeneration.
This degenerative pathology of the retina affects about 700,000 people in Spain, 1.5% of its population, and is expected to be the pathologies associated with blindness that grow most in the coming years.
This disease represents the first cause of blindness in developed countries and its appearance is associated with age, smoking, family history and previous surgery of cataract, as removal of the lens removes the natural protective filter of the retina, Associated with other factors, can cause macular involvement in some cases.
Dr. Miranda, under the supervision of Dr. Jerónimo Lajara, Mª del Mar Martínez and Pablo Conesa, has conducted her research study with one hundred and twenty-five patients of the Retina Medical Unit of the Ophthalmology Service of the General University Hospital of Santa Lucía, To determine the influence of polymorphisms (genetic variations) on four genes in response to treatment with ranibizumab, one of the most used for this degenerative disease and currently has a success rate of 50-60%.
Source: UCAM
Privacy policy
- Legal notice
- Cookies